Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • PDGFR
    (9)
  • c-Kit
    (9)
  • VEGFR
    (8)
  • FLT
    (6)
  • FGFR
    (5)
  • TAM Receptor
    (5)
  • Apoptosis
    (4)
  • c-Met/HGFR
    (3)
  • Autophagy
    (2)
  • Others
    (9)
Filter
Search Result
Results for "

RTK

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    34
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Natural Products
    1
    TargetMol | Natural_Products
  • Recombinant Protein
    11
    TargetMol | Recombinant_Protein
  • Antibody Products
    5
    TargetMol | Antibody_Products
sitravatinib
MGCD516, MG516
T43491123837-84-2
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα β, PDGFR, and Axl.
  • Inquiry Price
Size
QTY
Dovitinib
TKI258, CHIR-258
T6289405169-16-6
Dovitinib is an orally active, multi-targeted tyrosine kinase (RTK) inhibitor with anti-tumor effects.
  • Inquiry Price
Size
QTY
pan-Raf/RTK inhibitor 1
T2041551980821-53-1
Pan-Raf RTK inhibitor 1 (compound I-16) is a potent pan-Raf inhibitor with IC50 values of 3.49 nM (BRafV600E), 8.86 nM (ARaf), 5.78 nM (BRafWT), and 1.65 nM (CRaf). It exhibits antiproliferative activity against various cancer cell lines and can be utilized in cancer research.
  • Inquiry Price
10-14 weeks
Size
QTY
FGF/PDGF/VEGF RTK Inhibitor
T71944144335-37-5
FGF PDGF VEGF RTK Inhibitor is a potent, reversible, atp-competitive inhibitor against pdgfrβ, fgfr-1, and vegfr-2 (ic50 = 20, 90, and 240 nm, respectively) and effectively suppresses vegf-stimulated proliferation of hmvecs (ec50 = 420 nm).
  • Inquiry Price
6-8 weeks
Size
QTY
MerTK/Axl-IN-1
T2005173036009-40-9
MerTK Axl-IN-1 (Compound A-910) is a potent and selective dual inhibitor of MerTK Axl, exhibiting IC50 values of 4.2 nM and 8.8 nM in Ba F3 cells, and 0.2 nM and 0.9 nM in HTRF cells, respectively. It effectively inhibits pMerTK in vivo and possesses a long half-life and high oral bioavailability.
  • Inquiry Price
3-6 months
Size
QTY
MerTK-IN-1
T2009633036376-10-7
MerTK-IN-1 (compound 31) serves as an inhibitor of MerTK, with the capability to bind to the target in vivo.
  • Inquiry Price
3-6 months
Size
QTY
Oxindole
Indolin-2-one
Fr1674159-48-3
Oxindole (Indolin-2-one) is an aromatic heterocyclic building block, and its 2-indolinone derivatives are lead compounds in kinase inhibitor research. The oxindole structure is utilized in receptor tyrosine kinase (RTK) inhibitors, such as SU4984 and intedanib, making the RTK family a significant therapeutic target for anti-cancer drug development.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Sunitinib
SU 11248
T0374L557795-19-4
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that inhibits VEGFR2 and PDGFRβ (IC50=80 2 nM). It exhibits antitumor activity and is used for treating kidney cancer and gastrointestinal tumors.
  • Inquiry Price
Size
QTY
Afatinib Dimaleate
BIBW2992, BIBW 2992MA2, Afatinib (BIBW2992) Dimaleate, Afatinib
T1773850140-73-7
Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity.
  • Inquiry Price
Size
QTY
Cabozantinib S-malate
XL184, Cabozantinib Malate, Cabozantinib
T17971140909-48-3
Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.
  • Inquiry Price
Size
QTY
Pexidartinib
PLX-3397
T21151029044-16-3
Pexidartinib (PLX-3397) is a capsule containing a small-molecule receptor tyrosine kinase (RTK) inhibitor targeting KIT, CSF1R, and FLT3, with potential antineoplastic activity.
  • Inquiry Price
Size
QTY
ON123300
T69201357470-29-1
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4 Ark5 PDGFRβ FGFR1 RET Fyn (IC50: 3.9 5 26 26 9.2 11 nM).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Sitravatinib malate
MGCD516 malate, MG-516 malate
T129252244864-88-6
Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.) , shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment.
  • Inquiry Price
1-2 weeks
Size
QTY
TNO155
Batoprotafib
T131761801765-04-7
TNO155 is a protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11) inhibitor(IC50 : 0.011 µM),with potential antineoplastic activity.
  • Inquiry Price
Size
QTY
Toceranib
PHA 291639E, SU11654
T13178356068-94-5
Toceranib (PHA 291639E) phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR, and Kit(with Kis of 5 and 6 nM for PDGFRβ and Flk-1 KDR, respectively), has antitumor and antiangiogenic activity.
  • Inquiry Price
7-10 days
Size
QTY
AG 1295
T1413771897-07-9
AG 1295, a selective inhibitor of platelet-derived growth factor receptor (PDGFR) tyrosine-kinase, effectively halts PDGFR autophosphorylation without impacting the autophosphorylation of the EGF receptor[1][2][3][4].
  • Inquiry Price
Size
QTY
JNJ-10198409
JNJ-​10198409
T15616627518-40-5
JNJ- 10198409 is a relatively selective and ATP competitive PDGF-RTK inhibitor (IC50=2 nM). JNJ-10198409 has good activity against PDGFR-β kinase (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
2-Methyl-3-phenylquinoxaline
T20151410130-23-1
2-Methyl-3-phenylquinoxaline (compound 38) serves as an effective inhibitor of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase (PDGF-RTK), exhibiting significant inhibitory activity against the full-length PDGFR kinase in intact cells (IC50 greater than 100 μM).
  • Inquiry Price
10-14 weeks
Size
QTY
Pirotinib
M8R6ETA52F, Kbp-5209
T2024031363358-86-4
Pirotinib is an orally available inhibitor targeting the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, exhibiting potential antineoplastic activity.
  • Inquiry Price
Size
QTY
EGF Receptor Peptide Acetate
EGF Receptor Peptide Acetate (96249-43-3 Free base), Epidermal Growth Factor Receptor Peptide Acetate(96249-43-3 Free base)
T21723L
Epidermal Growth Factor Receptor Peptide Acetate exists on the cell surface and is activated by the binding of its specific ligands.EGFR belongs to the ErbB family of receptor tyrosine kinases (RTK).
  • Inquiry Price
Size
QTY
4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline
T36102183322-18-1
4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline is a building block and synthetic intermediate.1,2,3,4,5It has been used as a precursor in the synthesis of receptor tyrosine kinase (RTK) inhibitors, dual RTK and histone deacetylase (HDAC) inhibitors, and anticancer compounds.1,2,3It is also a synthetic intermediate in the synthesis of EGFR inhibitors, including erlotinib , with antiproliferative activity.4,5
  • Inquiry Price
7-10 days
Size
QTY
SAR125844
SAR125884
T54671116743-46-4
SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol L)
  • Inquiry Price
6-8 weeks
Size
QTY
SAR125884 hydrochlorid (1116743-46-4(free base))
T5677
SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).
  • Inquiry Price
Size
QTY
SSR128129E
SSR 128129E
T6082848318-25-2
SSR128129E (SSR) is an allosteric and orally-active FGFR1 inhibitor (IC50: 1.9 μM), but not affecting other related RTKs.
  • Inquiry Price
Size
QTY